Rare Arrhythmias
Arrhythmias encompass a wide range of heart rate and rhythm abnormalities, posing significant health risks to an individual's health. Our company stays at the forefront of rare arrhythmia therapeutic research and development, offering tailored solutions for researchers and scientists in this field to advance drug development project progress.
Overview of Rare Arrhythmias
Arrhythmia signifies an irregular heart rhythm, with a normal sinus rhythm being the standard. An impulse originates in the sinoatrial (SA) node, travels through, and is slowed down as it passes through the atrioventricular (AV) node. It then continues through the bundle of His, the left and right bundle branches, and finally reaches the Purkinje fibers. Any deviation from this normal conduction pathway results in an arrhythmia. Individuals with an arrhythmia may display a variety of symptoms, ranging from no symptoms to sudden cardiac arrest.
Fig.1 Mechanisms and therapeutic targets in LQTS and SQTS. (Crotti, L., et al., 2020)Classification of Rare Arrhythmias
Rare arrhythmias can be sorted into acquired and inherited types based on their causes. The development of rare arrhythmias involves intricate mechanisms that interfere with the heart's normal electrical signaling. These mechanisms may result from genetic mutations impacting ion channels, structural irregularities in the heart, or underlying medical conditions. Rare arrhythmias can also be subdivided into primary electrical disorders of the heart and arrhythmias in specific settings.
- Primary electrical disorders of the heart
Disorders predisposing to supraventricular tachyarrhythmias, disorders predisposing to ventricular tachyarrhythmias, disorders predisposing to bradyarrhythmias, and others. - Arrhythmias in specific settings
Iatrogenic arrhythmias or heart rhythm disturbances related to drug therapy, arrhythmias associated with metabolic disorders, and others.
Fig.2 Ivabradine-induced arrhythmias. (Tisdale, J. E., et al., 2020)Therapeutics Development for Rare Arrhythmias
| Diseases | Drug Names | Mechanism of Action | Targets | Research Phase |
|---|---|---|---|---|
| Brugada Syndrome | Quinidine | Inhibits the transient outward potassium current | SCNA | Clinical trials |
| Cilostazol | Acts as effective and selective inhibitors of phosphodiesterase 3 subtype PDE3A | PDE3A | Clinical trials | |
| AAV9-MOG1 | Enhances the transport of Nav1.5 to the cell membrane surface | SCN5A | Preclinical research | |
| Short QT Syndrome | Disopyramide | Blocks the rapid inward sodium current in the myocardium | SCNA | Clinical trials |
| Catecholaminergic Polymorphic Ventricular Tachycardia | Esmolol | Functions as a cardiac-selective adrenergic beta receptor blocker | β1-adrenergic receptor | Clinical trials |
| Aladorian | Serves as a type of ryanodine receptor (RyR) modulator with antiarrhythmic effects | RyR | Phase II | |
| CRD-4730 | Inhibits calmodulin-dependent protein kinase II (CaMKII) | CaMKII | Phase II |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Our team comprises seasoned professionals with profound knowledge of rare arrhythmias. We utilize cutting-edge technologies and research methods to drive progress in understanding and treating these conditions. From preclinical research to therapeutic development, we offer comprehensive services encompassing diagnostics, therapeutics, and disease model development for rare arrhythmias.
Types of Rare Arrhythmias
| A-F | |
|---|---|
| Atypical Atrial Flutter | Congenital Heart Block (CHB) |
| Brugada Syndrome | Early Repolarization Syndrome (ERS) |
| Bundle Branch Reentry Ventricular Tachycardia (BBRVT) | Familial Sick Sinus Syndrome |
| Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | Fast-slow AVNRT |
| H-M | |
| His Bundle Tachycardia | Incessant Ventricular Tachycardia |
| Idiopathic Ventricular Fibrillation | Long QT Syndrome (LQT) |
| Idiopathic Ventricular Tachycardia | Multifocal Atrial Tachycardia |
| P-V | |
| Permanent Form of Junctional Reciprocating Tachycardia (PJRT) | Sinoatrial Reentry Tachycardia |
| Preexcitation Syndromes | Slow-slow AVNRT |
| Progressive Cardiac Conduction Defect (PCCD) | Torsades De Pointes |
| Short QT Syndrome (SQT) | |
Therapeutic and Animal Model Development Services
Animal Model Development Services
- Chemical-induced Model
- Diet-induced Model
- Genetically Engineered Model
- Immunogenicity Model
- Surgical Model
- Transplant Model
We deliver customized preclinical research services tailored to each project, including pharmacokinetic studies and drug safety evaluations. Clients who choose our services will benefit from our steadfast dedication to excellence, innovation, and our commitment to making a substantial impact on rare arrhythmia drug development. If you are interested in our services, please feel free to contact us for more information.
References
- Crotti, Lia et al. "Heritable arrhythmias associated with abnormal function of cardiac potassium channels." Cardiovascular research 116.9 (2020): 1542-1556.
- Tisdale, James E et al. "Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association." Circulation 142.15 (2020): e214-e233.
For research use only, not for clinical use.